TECH

NEUTRALM&A

Bio-Techne Corp

2026-09-23

Price

$72.52

+0.15%

This is the 2026-09-23 snapshot — the signals and analysis for TECH as of this single trading day.

View full TECH research hub →

Score10.0Priority

Signals6/8 DNA0/13 Act · 1/4 Risk

SentimentNEUTRALScore: 6

Volume1.1xvs 20d avg

Analysis

Bio-Techne (TECH) is trading purely as a merger arbitrage play following its pending $73.00 per share all-cash acquisition by Merck KGaA. This M&A anchor perfectly explains the exceptionally low 3.5% annualized volatility and the 'QUIET_STORM' technical signal, as price action remains pinned just below the buyout level. Furthermore, today's shareholder approval and the recent expiration of the HSR antitrust waiting period have significantly de-risked the transaction timeline. Finally, the current 'RISK_ON' macro regime provides high conviction that financing and broader market conditions will not disrupt this late-stage deal, leaving only a tight spread to be captured by arbitrageurs.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKWEAK FINISH

Key Takeaways

Actionable Thesis: TECH offers a low-volatility merger arbitrage opportunity, with shares trading at $72.52 against a hard $73.00 cash buyout price.
Key Risk: Unforeseen regulatory blockage outside the US (HSR has already expired) could cause the deal to collapse, risking a severe drop to standalone valuation.
What to Watch: Updates on remaining international regulatory approvals ahead of the targeted late 2026 or early 2027 closing date.

← Back to 2026-09-23 View Full TECH History →Yahoo Finance &nearr;